Description

EORTC research on the Gastrointestinal tract focuses on expanding what we know about the genetic, epigenetic and immunologic backgrounds of gastrointestinal tumour diseases. Clinical trials in this field focus on preclinical to clinical interaction and integrating early drug development, ensuring that new aspects of tumour biology are being investigated with appropriate contemporary technology. The ultimate goal is to better inform treatment decisions by identifying patient subsets most likely to benefit from a given therapy.

Main Achievements

Published joint Clinical Practice Guidelines on the management of hepatocellular carcinoma with the European Association for the Study of the Liver (EASL) More information ; More information. These define the use of surveillance, diagnosis and therapeutic strategies recommended for patients with HCC.

The CLOCC randomised controlled phase II study performed in patients with liver metastases from colorectal cancer suggests that radiofrequency ablation of liver lesions prolongs survival (Ruers T et al. J Natl Canc Inst 2017 [in press]). Based on these findings, the group is now starting a study combining this approach with immunotherapy (ILOCC study).

Long-term follow up data confirm the significant improvement in progression-free survival of perioperative chemotherapy in resectable liver metastases from colorectal cancer More information.

Research Group

Group documents
  • Chair

    Michel Ducreux

    Institut Gustave Roussy

    Villejuif, France

  • Secretary

    Florian Lordick

    University Cancer Center Leipzig

    Leipzig, Germany

  • Treasurer

    Theo Ruers

    The Netherlands Cancer Institute-Antoni Van Leeuwenhoekziekenhuis

    Amsterdam, Netherlands